MedTrace Logo

G7 Freedom Constrained Vivacit-E Liners

NCT05587244 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2025-10-20

No results posted yet for this study

Summary

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

Conditions

  • Osteoarthritis, Hip
  • Rheumatoid Arthritis
  • Non-Union Fracture
  • Trochanteric Fractures
  • Femoral Neck Fractures
  • Avascular Necrosis
  • Dislocation, Hip

Interventions

DEVICE

Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners

Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hillary Overholser · Zimmer Biomet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-08
Primary Completion
2037-12-31
Completion
2038-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587244 on ClinicalTrials.gov